These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32684074)

  • 21. Cytokines in Thyroid-Associated Ophthalmopathy.
    Zhang P; Zhu H
    J Immunol Res; 2022; 2022():2528046. PubMed ID: 36419958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on 'Acute thyroid eye disease (TED): principles of medical and surgical management'.
    Litwin AS; Malhotra R
    Eye (Lond); 2014 May; 28(5):632. PubMed ID: 24603423
    [No Abstract]   [Full Text] [Related]  

  • 23. Current trends in the management of thyroid eye disease.
    Rao R; MacIntosh PW; Yoon MK; Lefebvre DR
    Curr Opin Ophthalmol; 2015 Nov; 26(6):484-90. PubMed ID: 26397888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Estrogen a Missing Culprit in Thyroid Eye Disease? Sex Steroid Hormone Homeostasis Is Key to Other Fibrogenic Autoimmune Diseases - Why Not This One?
    FitzPatrick AM
    Front Immunol; 2022; 13():898138. PubMed ID: 35784325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical Guidelines Management of Graves Ophthalmopathy.
    Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
    Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The eye and thyroid disease.
    Kuriyan AE; Phipps RP; Feldon SE
    Curr Opin Ophthalmol; 2008 Nov; 19(6):499-506. PubMed ID: 18854695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy.
    Strianese D; Rossi F
    Eye (Lond); 2019 Feb; 33(2):191-199. PubMed ID: 30610229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
    Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
    Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Survey on the Management of Thyroid Eye Disease Among American and European Thyroid Association Members.
    Brito JP; Nagy EV; Singh Ospina N; Zˇarković M; Dosiou C; Fichter N; Lucarelli MJ; Hegedüs L
    Thyroid; 2022 Dec; 32(12):1535-1546. PubMed ID: 35946071
    [No Abstract]   [Full Text] [Related]  

  • 32. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical Treatment of Graves' Orbitopathy.
    Salvi M; Campi I
    Horm Metab Res; 2015 Sep; 47(10):779-88. PubMed ID: 26361263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
    Wall JR; Lahooti H
    Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Biological Agents and Immunomodulators in Treatment Strategies for Thyroid Eye Disease: An Evidence-based Review.
    Ginter A; Migliori ME
    R I Med J (2013); 2016 Jun; 99(6):26-9. PubMed ID: 27247969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teprotumumab for the treatment of chronic thyroid eye disease.
    Ugradar S; Kang J; Kossler AL; Zimmerman E; Braun J; Harrison AR; Bose S; Cockerham K; Douglas RS
    Eye (Lond); 2022 Aug; 36(8):1553-1559. PubMed ID: 34244669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Updates on the understanding and management of thyroid eye disease.
    Men CJ; Kossler AL; Wester ST
    Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
    Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
    Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
    [No Abstract]   [Full Text] [Related]  

  • 39. [Management of Graves' ophthalmopathy].
    Schalin-Jäntti C
    Duodecim; 2010; 126(20):2431-7. PubMed ID: 21125757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
    Krassas GE; Gogakos A
    J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.